Annuncio • Feb 27
QScreen AI Inc. announced that it expects to receive CAD 0.5 million in funding QScreen AI Inc. announced a non-brokered private placement up to 10,000,000 units at a price of CAD 0.05 per Unit, for aggregate gross proceeds to the Company of up to CAD 500,000 on February 26, 2026. Each Unit will be comprised of one common share of the Company and one half of one common share purchase warrant. Each Warrant will entitle the holder thereof to purchase one half Common Share of the Company at a price of CAD 0.15 for a period of 36 months following the closing date of the Offering. If, following four months and a day after the Closing Date, the volume weighted average price of the Common Shares on the CSE is equal to or greater than CAD 0.30 for any 10 consecutive trading days, the Corporation may, upon providing written notice to the holders of Warrants, accelerate the expiry date of the Warrants to the date that is 30 days following the date of such written notice. New Risk • Dec 03
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 36% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (44% average weekly change). Negative equity (-CA$905k). Shareholders have been substantially diluted in the past year (36% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$14.3m market cap, or US$10.2m). Annuncio • Oct 21
Predictmedix AI Inc. announced that it expects to receive CAD 0.9 million in funding Predictmedix AI Inc. announced a non-brokered private placement of 18,000,000 Units of the company at a price per share of CAD 0.05 to raise a total gross proceeds of CAD 900,000 on October 20, 2025. Each unit will be composed of one common share of the company and one-half of one common share purchase warrant. Each warrant will entitle the holder thereof to purchase one-half common share of the company at a price of 15 cents for a period of 36 months following the closing date of the offering . Annuncio • Sep 24
Predictmedix AI Announces Multi-Vertical Growth Strategy to Become an AI Health-Technology Leader Predictmedix AI Inc. outlined a strategic plan to evolve from a single-product health-screening company into a diversified, AI-driven health-technology enterprise with three complementary growth platforms. Three Growth Platforms: Clinical-Trial AI Platform - Primary Near-Term Driver: Predictmedix is developing an adaptive-AI engine designed to simulate, optimize, and predict outcomes across multi-site clinical trials--addressing a global clinical trials market projected to reach USD123.5 billion by 2030, growing at a CAGR of ~6.5 % from 2024 to 20301. The SaaS-based platform is intended to provide trial simulation, cross-trial learning, cost/outcome modeling, and full regulatory traceability. SmartHealth AI Stations - Global Commercialization: The Company's contactless, screening systems have demonstrated approximately 95% accuracy in detecting impairment, infectious disease, and multiple vital signs, supported by independent, multi-center clinical validation. Predictmedix is assessing regulatory requirements in multiple jurisdictions, including Southeast Asia, and plans to initiate formal medical-device certification processes as a next step toward global deployment for enterprise health & safety, hospital triage, and government health programs. Consumer Vital-Scanning Mobile Application - Direct-to-Consumer Entry: A planned mobile application will leverage Predictmedix's patented imaging technology to deliver vital-sign monitoring through a smartphone, extending the Company's platform into the growing digital-health and telehealth markets. Strategic Rationale: Recurring revenue potential: SaaS subscriptions for the Clinical-Trial AI platform; Screening-as-a-Service for enterprises and hospitals; consumer subscriptions for the mobile app; Defensible IP: Proprietary adaptive-simulation engine and patented multispectral imaging algorithms; Large addressable markets. Annuncio • Aug 20
Predictmedix AI Inc., Annual General Meeting, Oct 28, 2025 Predictmedix AI Inc., Annual General Meeting, Oct 28, 2025. Location: ontario, toronto Canada Annuncio • Jul 02
Predictmedix AI Expands into Mobile Diagnostics with New AI-Driven Diabetes Screening Platform Predictmedix AI Inc. is expanding into the direct-to-consumer market with a mobile solution designed to deliver rapid, non-invasive diabetic screening -- with India identified as the initial launchpad for this transformative initiative. Leveraging the company's proprietary AI technology, the platform is intended to empower millions with instant access to diabetic risk assessments using only a smartphone, eliminating the need for blood draws, lab visits, or clinical infrastructure. By combining advanced facial and biometric analysis with seamless smartphone delivery, the solution brings accessible, affordable, and scalable diabetic screening to some of the most underserved populations across India. This milestone represents a significant step in Predictmedix AI's broader vision to reshape global healthcare delivery and accelerate the adoption of AI-enabled, mass-scale preventive health solutions. Key Features: Instant Diabetic Risk Scoring via smartphone. AI-driven facial and biometric analysis based on Predictmedix's proven non-invasive screening platform. User-friendly design with multilingual support for broad accessibility. Secure, privacy-compliant data handling, in line with India's Digital Personal Data Protection (DPDP) Act. Strategic Significance: India's diabetes epidemic is accelerating, with estimates projecting nearly 1 in 3 adults to be diabetic or diabetic by 2045. Simultaneously, smartphone adoption now exceeds 1.1 billion users -- a convergence that creates a once-in-a-generation opportunity for mobile-first, AI-powered health solutions. platform is uniquely positioned to: Capture significant market share in a high-need, high-growth region. Generate recurring revenue streams through direct-to-consumer and B2B channels. Align with public health priorities of governments, NGOs, and large employers. Scale globally with minimal marginal cost, leveraging cloud-based delivery. New Risk • Jun 30
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$577k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$577k free cash flow). Share price has been highly volatile over the past 3 months (29% average weekly change). Negative equity (-CA$798k). Revenue is less than US$1m. Market cap is less than US$10m (CA$4.81m market cap, or US$3.51m). Minor Risk Shareholders have been diluted in the past year (28% increase in shares outstanding). Annuncio • Apr 11
Predictmedix AI Screening Technology Emerges as Strategic Asset Amid FDA’s Regulatory Shift Away from Animal Testing Predictmedix AI Inc. welcomes the U. S. Food and Drug Administration’s (FDA) groundbreaking move to phase out mandatory animal testing in drug development. As the pharmaceutical and biotech industries pivot toward more ethical and technologically advanced methodologies, Predictmedix’s Smart Health AI Stations stand out as a scalable, non-invasive, and human-centric alternative for preclinical and clinical evaluations. This regulatory shift signals a new era in drug development—one that emphasizes innovation, speed, and safety in human trials. Predictmedix’s proprietary AI platform, capable of real-time physiological and cognitive assessment, offers a powerful solution for pharmaceutical companies seeking to accelerate human-based research while ensuring rigorous data integrity and compliance. Deployed across hospitals, research institutions, and occupational health settings, the AI-powered stations continuously monitor vitals, impairment, fatigue, and infection markers using advanced algorithms. The technology reduces dependency on invasive procedures and offers high-throughput data collection essential for modern clinical trials. Predictmedix AI’s technology serves as an alternative to animal models by analyzing real-time human biomarkers to predict physiological responses. Traditional drug testing relies on animal models to estimate how a substance will affect humans, but biological differences between species often limit their accuracy. In contrast, Predictmedix AI uses advanced machine learning and sensor technology to assess key human health indicators—such as heart rate, temperature, blood pressure, respiration rate and other vital signs—providing direct, human-relevant data for evaluating drug responses. This approach reduces reliance on animal testing while offering more precise insights into human physiology, ultimately improving drug development and safety assessments. With over 500,000 scans conducted, the platform has been rigorously validated, achieving up to 95% accuracy in detecting vital signs, ensuring reliable and precise health assessments. Core Advantages of Predictmedix’s Smart Health AI Stations: AI-Driven, Real-Time Assessments – Delivering objective, consistent evaluations across multiple biomarkers. Scalable and Modular – Easily deployable across trial sites or research institutions. Non-Invasive and Contactless – Enhancing patient compliance and safety. Compliant and Secure – Built with data privacy and regulatory standards in mind. Predictmedix AI is in active discussions with pharmaceutical and clinical research organizations to integrate its AI health screening stations into decentralized and adaptive trial frameworks, positioning itself as a foundational player in the post-animal testing era. Annuncio • Apr 08
Predictmedix AI Inc. Surpasses 500,000 Scans with Smart Health AI Stations Predictmedix AI Inc. announced a significant milestone: its Smart Health AI Stations have successfully completed over 500,000 individual scans. This achievement highlights the scalability, precision, and real-world impact of Predictmedix AI's cutting-edge machine learning technology, transforming health and safety standards across healthcare, corporate, and public sectors. The completion of 500,000 scans showcases the power of Predictmedix AI's non-invasive, AI-powered screening tools, designed to deliver unmatched accuracy and efficiency. By integrating advanced computer vision with adaptive machine learning, the Smart Health AI Stations detect critical health risks--including infectious disease symptoms, mental health indicators, and impairment--in real time. With every scan, the system's algorithms become sharper, enabling faster, more reliable interventions and fostering safer environments for organizations and communities worldwide. From rapid vitals screening to impairment detection, Predictmedix AI's technology offers privacy-focused, actionable health insights with minimal disruption. Its growing mental health assessment capabilities are proving especially valuable, enabling employers to identify stress, fatigue --supporting employee well-being through proactive, data-driven care. This versatility makes the Smart Health AI Stations a game-changer across industries. With this milestone, Predictmedix AI solidifies its position as a leader in AI-powered health innovation. The company is poised for continued growth, with plans to strengthen industry partnerships, integrate multimodal health data, and explore new frontiers in telemedicine and personalized analytics. As the demand surges for ethical, automated AI solutions, Predictmedix AI remains committed to advancing tools that prioritize safety, health, and well-being on a global scale. New Risk • Apr 04
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (50% average weekly change). Negative equity (-CA$914k). Revenue is less than US$1m. Market cap is less than US$10m (CA$5.60m market cap, or US$3.94m). Minor Risk Shareholders have been diluted in the past year (24% increase in shares outstanding). Annuncio • Feb 28
Predictmedix AI Inc. Launches Advanced AI Health Stations to Target the US Market Predictmedix AI Inc. announced that it is launching its enhanced Smart Health AI Stations across the United States, positioning itself to capitalize on the rapidly expanding population health management market. This strategic launch, in partnership with Manchester Marketing Group Inc., introduces advanced AI-powered health assessments featuring real-time vitals screening and substance induced impairment detection. Ten units are under consideration for potential showcasing to corporate and government entities nationwide in the USA. Manchester Marketing Group Inc. is based out of the USA and is working with partners for the North American, Central American and South American Market along with the Caribbean. The Smart Health AI Station provides instant, non-contact health screenings using AI technology to detect potential health risks and promote safer environments. Market Opportunity: The population health management market, valued at USD 32.94 billion in 2023, is projected to surge to USD 126.16 billion by 2032, exhibiting a CAGR of 16.6%. North America holds a dominant 64.81% market share. New Risk • Jun 30
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.6m free cash flow). Share price has been highly volatile over the past 3 months (34% average weekly change). Negative equity (-CA$144k). Earnings have declined by 10% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$3.01m market cap, or US$2.20m). Minor Risk Shareholders have been diluted in the past year (3.2% increase in shares outstanding). New Risk • Jun 04
New major risk - Negative shareholders equity The company has negative equity. Total equity: -CA$144k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.6m free cash flow). Share price has been highly volatile over the past 3 months (29% average weekly change). Negative equity (-CA$144k). Earnings have declined by 10% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$3.76m market cap, or US$2.74m). Minor Risk Shareholders have been diluted in the past year (11% increase in shares outstanding). Annuncio • Apr 27
Predictmedix Inc. Expands Reach and Impact in Healthcare Transformation Efforts Predictmedix Inc. announced significant progress in revolutionizing the healthcare industry through innovative AI solutions. Over the past quarter, Predictmedix AI has achieved several milestones, including the successful deployment of its AI-powered solutions in multiple healthcare facilities. These include Trinity hospital along with government hospitals, particularly Bps Women's College Hospital and government training institutes in New Delhi, where Predictmedix AI's Safe Entry Stations continue to operate effectively. In addition to its presence in healthcare facilities, Predictmedix AI has enhanced its technology for screening for Post-Traumatic Stress Disorder (PTSD) and has successfully deployed it in hospital units, further expanding its capabilities to address critical healthcare needs. In addition to the utility of the tech for monitoring mental well-being of military personnel and Veterans, the technology also has applications in Education and workplace segment.TSD screening can be deployed to assess emotional well-being of employees as well as emotional well-being of students in the education segment. Furthermore, Predictmedix AI is collaborating with distribution partners in the US to develop relationships with key segments in the US, extending its reach beyond traditional healthcare settings. This collaboration reflects Predictmedix AI's commitment to exploring new avenues for leveraging its AI technology to improve health outcomes. Moreover, Predictmedix AI has developed a go-to-market strategy in Indonesia, utilizing its Safe Entry Stations as a "fit for duty" solution for workplaces. By expanding its focus beyond traditional healthcare settings, Predictmedix AI aims to make a broader impact on public health and safety. Annuncio • Jan 11
Predictmedix AI Inc. Unveils Technological Advances Including Publishing of Peer-Reviewed Paper Predictmedix AI Inc. announced significant technological advances within its Safe Entry Station (SES) technology, featuring innovations that solidify the company's commitment to pioneering advancements in the field. These breakthroughs set the stage for highly anticipated commercial deals, further establishing Predictmedix AI's position as a leader in the industry. The enhanced capabilities of SES include: Emotional State Identification: SES can now discern the emotional state of individuals, introducing a new dimension to health assessments by accurately identifying happiness, neutrality, surprise, joy, fear, and frustration. PRQ Assessment: PRQ is now seamlessly integrated into the scanning process, providing a comprehensive health evaluation beyond previously announced parameters. The pulse-respiration quotient (PRQ) reflects properties of the complex interplay between cardiac and respiratory activities. The pulse-respiration quotient metric measures to what extent this interplay is functioning normally. A low or high score would indicate that heart rate and/or breathing rate are disproportionate, which may indicate that both the heart and the lungs are working inefficiently. Stress Monitoring: A stress monitoring code has been successfully deployed, enabling SES to identify stress or a stress-free state in individuals undergoing scanning, offering valuable insights into mental well-being. Face Verification Accuracy:igorously tested on more than 500 subjects, face verification technology achieves an impressive accuracy rate of over 99%, ensuring robust and reliable identity verification. Publishing of peer reviewed publication on Facial PPG Signals for Blood Pressure Estimation. In a move towards personalized healthcare, Predictmedix AI introduces a novel machine learning approach utilizing Photo Plethysmography (PPG) signals for precise blood pressure estimation. Recognizing the global prevalence of hypertension, the company leverages wearable devices to obtain facial PPG signals, offering valuable physiological information related to cardiovascular activity. Through advanced machine learning algorithms, including deep learning architectures and feature extraction methods, Predictmedix AI aims to establish a robust model for blood pressure estimation using facial image analysis. The methodology involves preprocessing PPG signals, extracting relevant features, and employing sophisticated machine learning models for regression analysis. Comprehensive experimentation with diverse datasets ensures the efficacy of this approach across various demographic groups and conditions. Results demonstrate promising accuracy and reliability in estimating blood pressure values, suggesting the potential for practical implementation in healthcare settings. The proposed technique opens a promising avenue for non-invasive and accessible blood pressure monitoring, contributing significantly to personalized healthcare and continuous health monitoring systems. Reported Earnings • Dec 29
Third quarter 2024 earnings released: CA$0.003 loss per share (vs CA$0.004 loss in 3Q 2023) Third quarter 2024 results: CA$0.003 loss per share (improved from CA$0.004 loss in 3Q 2023). Net loss: CA$449.4k (loss narrowed 2.1% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings. Annuncio • Dec 20
Predictmedix Ai Inc. Elevates Safe Entry Stations with Cutting-Edge Facial Recognition Technology Predictmedix AI Inc. announced a strategic enhancement to its Safe Entry Stations platform-the integration of advanced facial recognition technology. The integration of advanced facial recognition technology into Safe Entry Stations marks a significant position in Predictmedix's commitment to advancing healthcare technology. This innovation highlights the dedication to pioneering solutions that enhance patient care and operational efficiency. The company are enthusiastic about the potential impact of this technology in transforming healthcare practices, enabling safer, more efficient environments. Its utilization is set to redefine access control and monitoring processes, enhancing safety protocols across various healthcare settings. Enhanced Security: The technology fortifies security by ensuring precise and efficient identification of individuals entering controlled environments. Contactless Access: Predictmedix AI's Safe Entry Stations, now equipped with facial recognition, enable contactless access, reducing physical contact points and contributing to a safer environment. User-Friendly Experience: The intuitive and user-friendly interface makes facial recognition accessible to a wide range of users, facilitating seamless and efficient entry processes. Real-Time Identification: The technology offers real-time identification capabilities, allowing swift and accurate recognition of individuals with minimal latency. Incorporating Advanced Healthcare Applications: Patient Identification and Record Management: AI-powered face verification ensures accurate patient identification, reducing errors and mix-ups in hospitals or clinics. It helps link patients to their electronic health records (EHRs) securely, minimizing the risk of misidentification and improving overall care delivery. Access Control in Healthcare Facilities: Facial recognition enhances security within healthcare premises, regulating access to restricted areas such as labs, pharmacies, or storage facilities for sensitive medications or equipment. This prevents unauthorized entry and improves overall safety. Medication Management: Face verification aids in medication dispensing by ensuring the right medication is given to the right patient, reducing errors in administering drugs and improving patient safety. Patient Monitoring and Engagement: In telemedicine or remote patient monitoring, facial recognition verifies patients during virtual consultations or when accessing healthcare apps. This strengthens security measures and ensures the right patient receives medical advice or monitoring services. Clinical Trials and Research: AI-based face verification aids in participant identification and tracking in clinical trials, ensuring accurate data collection and maintaining the integrity of research studies. Reducing Medical Fraud and Identity Theft: Facial recognition helps reduce instances of medical fraud by verifying patients' identities and preventing individuals from using stolen identities to access healthcare services or prescriptions. Patient Experience and Customization: Facial recognition technology personalizes patient experiences by recognizing individuals when they arrive at healthcare facilities, providing tailored information or services, and improving overall satisfaction. Annuncio • Nov 15
Predictmedix AI Inc. Announces Successful Clinical Validation At the University of Raharja, Indonesia, Demonstrating 95% Accuracy in Vital Sign Detection Predictmedix AI Inc. announce the results of a clinical validation conducted in collaboration with the esteemed University of Raharja in Indonesia. Clinical validation represents a major stride in advancing AI technology's role in enhancing safety culture and prioritizing the well-being of individuals. The study focused on developing AI-based software with external support, emphasizing a non-invasive approach to capture vital signs like heart rate, respiration rate, height, body temperature, and blood pressure. Notably, no recognizable facial images were captured to maintain confidentiality and privacy. Predictmedix AI's Solution Features: Face Detection & Single Lively Face, SOP Violation Detection (e.g., closed eyes, side face, mask on, glasses on), Body Temperature Detection, Heart Rate Monitoring, Respiration Rate Monitoring, SpO2 Measurement, Height Assessment, Blood Pressure Measurement. The rigorous testing phase involved scanning approximately 6,000 subjects, resulting in a remarkable 95% accuracy across critical parameters. The AI algorithms undergo continuous refinement, ensuring reliability, consistency, and accuracy in vital sign readings. Reported Earnings • Oct 01
First half 2024 earnings released: CA$0.009 loss per share (vs CA$0.006 loss in 1H 2023) First half 2024 results: CA$0.009 loss per share (further deteriorated from CA$0.006 loss in 1H 2023). Net loss: CA$1.17m (loss widened 71% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings. Annuncio • Sep 30
Predictmedix AI Inc., Annual General Meeting, Dec 07, 2023 Predictmedix AI Inc., Annual General Meeting, Dec 07, 2023. Board Change • Aug 31
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Tom Sipos was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annuncio • Jul 22
Predictmedix AI Inc. Unveils Cutting-Edge Contactless Integrative AI Solutions for Healthcare in India Predictmedix AI Inc. announced its ground-breaking contactless integrative AI solutions for healthcare, poised to revolutionize the industry in India. Leveraging the power of advanced AI algorithms and technology, Predictmedix aims to enhance the efficiency, accuracy, and safety of healthcare practices across the country. A report on the National Strategy for Artificial Intelligence by the NITI Aayog showed that shortage of qualified healthcare professionals and non-uniform accessibility to healthcare across the country prevails. India has only 64 doctors available per 100,000 people compared to the global average of 150. This significant disparity highlights the urgent need for innovative solutions to bridge the healthcare gap and improve healthcare outcomes for the Indian population. With the growing demand for innovative healthcare solutions, Predictmedix is at the forefront of developing advanced AI-powered tools designed to transform the way medical professionals provide care. By eliminating the need for physical contact, these cutting-edge solutions address the challenges and contribute to the overall improvement of healthcare delivery. Predictmedix's contactless integrative AI solutions combine computer vision, thermal imaging, and predictive analytics to enable seamless and efficient healthcare interactions. These solutions offer a range of capabilities, including contactless temperature screening, symptom analysis, mental health assessments, and substance abuse detection, among others. By employing sophisticated algorithms, Predictmedix ensures accurate and reliable results, empowering healthcare providers with valuable insights to make informed decisions. Aligned with the vision of the Atmanirbhar Bharat Digital Mission (ABDM), Predictmedix's contactless integrative AI solutions exemplify India's commitment to harnessing cutting-edge technology to address critical healthcare challenges. ABDM, initiated by the Government of India, seeks to empower citizens with digital services and solutions while fostering self-reliance in the digital domain. Predictmedix's AI solutions have already garnered recognition and adoption globally, earning accolades for their potential to reshape healthcare systems. With the launch of these innovative offerings in India, Predictmedix aims to collaborate with healthcare providers, government institutions, and industry stakeholders to drive positive change and improve healthcare outcomes for the nation's population. Annuncio • Jun 22
Predictmedix Inc. announced that it has received CAD 1.051 million in funding On June 21, 2023, Predictmedix Inc. closed the transaction. Annuncio • Jun 14
Predictmedix Inc. Advances Commercialization Plans for its AI-Powered Technology Suite in Key Asian Markets Predictmedix Inc. announced substantial progress in its ongoing partnership with a Indonesian university, as it advances through the validation process for regulatory approval of its AI-product suite as a medical device in Indonesia. Additionally, Predictmedix has actively engaged with government officials from the technology sector to explore the extensive healthcare applications of its Safe Entry solution at a scalable level. Over the past three weeks, Predictmedix has had the privilege of working closely with government officials with the aim to explore diverse applications using the company's AI products and technology which can integrate seamlessly into pre-existing systems for rapid scalability. Furthermore, Predictmedix's ongoing partnership with key Indonesian university plays a pivotal role in its commercialization plan throughout lucrative Asian regions. Through comprehensive testing and analysis, the company aims to demonstrate the efficacy and accuracy of its AI technology and products in diagnosing a broad range of medical conditions and screening for key vitals as part of standard operating procedures in healthcare. Predictmedix's partnership with the university has been essential in advancing its AI-powered technology applications and providing access to diverse patient populations, enabling real-world validation of its cutting-edge solutions. Obtaining regulatory approval for medical devices is an integral aspect of any product prior to being commercialized in healthcare settings. As part of the Predictmedix's commercialization plan, regulatory approval for the company's suite of AI-products in Indonesia is underway. The company is committed to meeting rigorous industry standards and regulations and is confident in obtaining regulatory approval, building on its track record of successful regulatory compliance. Annuncio • Jun 01
Predictmedix Inc. announced delayed 20-F filing On 05/31/2023, Predictmedix Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC. Annuncio • May 18
Predictmedix Inc. Unveils Revolutionary Fitness Scan Vertical for Athletes, Teams, and Sports Federations Predictmedix Inc. announced the launch of its ground-breaking fitness scan vertical tailored specifically for athletes, teams, and sports federations. Leveraging state-of-the-art AI technology, Predictmedix's fitness scan vertical delivers a comprehensive analysis of an athlete's fitness level, empowering them to optimize their training and elevate their performance. The innovative fitness scan vertical by Predictmedix harnesses advanced machine learning algorithms to provide athletes with precise and personalized insights into their physical capabilities. By evaluating key performance factors such as strength, endurance, flexibility, and cardiovascular health, the platform offers athletes a holistic understanding of their fitness profile. This invaluable information enables athletes to identify areas for improvement and craft customized training programs tailored to their unique needs and aspirations. Market research indicates a significant growth opportunity for Predictmedix's new fitness scan vertical. The Global Health and Fitness Club Market is projected to reach USD 169,696.72 Million by 2030, exhibiting a remarkable compound annual growth rate (CAGR) of 7.67% from 2023 to 2030.1 With its expertise in AI-driven health technologies and in response to market demand, Predictmedix is poised to revolutionize fitness assessment and optimization. Annuncio • May 11
Predictmedix Launches Ai-Driven Comprehensive Triage Solution with Expanded Vital Parameter Measurements for High Traffic Hospitals in Targeted Asian Region Predictmedix Inc. announced the launch of its ground-breaking complete triage solution. Predictmedix's cutting-edge system encompasses a wide range of parameters, including 8 new parameters, providing an unparalleled level of accuracy and efficiency in healthcare assessments. The technology uses advanced artificial intelligence algorithms to analyze patient vital signs and provide medical staff with real-time information to help make informed treatment decisions. Hospitals globally are facing unprecedented challenges in managing patient care. Predictmedix's triage solution aims to improve the efficiency of hospital workflows and reduce the time it takes to diagnose and treat patients. Recognizing the urgent need for efficient triage solutions, Predictmedix has initiated deployments of its comprehensive system in major hospitals in a targeted geography in Asia where the number of patients coming in a day often exceeds 1000. The company's triage solution has been seamlessly integrated into certain hospitals' existing healthcare infrastructure, ensuring a smooth transition and minimal disruption. Since its deployment, Predictmedix's Triage Solution has received an overwhelmingly positive response from patients, doctors, and healthcare professionals. Its accuracy, efficiency, and ability to streamline the triage process have is proving to save valuable time and resources. Patients have expressed their satisfaction with the speed and thoroughness of the assessments, while doctors and healthcare professionals have praised the system for its effectiveness and potential to enhance patient care. Predictmedix's solution uses advanced computer vision and artificial intelligence technology to analyze vital signs. The system can identify patterns in the data and alert medical staff to potential health issues before they become critical. The company's Triage Solution incorporates the measurement and analysis of the following vital parameters: temperature, eye redness, heart rate, respiration rate, fatigue, weight, BMI, BMR, blood pressure, heart rate variability, skeletal muscle, resting metabolism, visceral fat, body fat percentage, bone mass, and alcohol/cannabis impairment. Predictmedix expects to scale up its operations in the near to mid term. The technology has the potential to revolutionize the way hospitals manage patient care and could be a game-changer for the healthcare industry. Annuncio • Feb 16
Predictmedix Inc. Announces Third-Party Independent Clinical Validation for Ai-Powered Screening Following 400 Patient Study at MGM Healthcare Predictmedix Inc. announced pivotal clinical validation data from one of the largest Government hospital groups in India for the company's AI-powered Safe Entry Stations. The third-party clinical findings show that Predictmedix's Safe Entry Stations accurately screen for various physiological conditions non-invasively - a pivotal milestone for the company's proprietary technology portfolio and for the global healthcare industry. The scope of the study was to determine the effectiveness of Predictmedix's AI-powered screening technology. The Safe Entry Station is a walk-thru system where an individual stands in front of the unit for 2-3 seconds while the multi-spectral imaging cameras gather the necessary information to determine the physiological state of the individual. Parameters like temperature, heart rate and respiration rate are collected non-invasively and the AI/ML algorithms compute a result. Vitals hold key insight into an individual's state, whether they're dealing with health complications, influenza, fatigue or even impairment. Safe Entry does not capture or store personal identity information, ever. Annuncio • Feb 14
Predictmedix Inc. announced that it has received CAD 0.6125 million in funding Predictmedix Inc. announced a non-brokered private placement of 12,250,000 units at a price of CAD 0.05 per unit for gross proceeds of CAD 612,500 on February 13, 2023. Each unit consists of one common share of the company and one common share purchase warrant, each Warrant entitles the holder to purchase one additional common share for a period of two years from closing at an exercise price of CAD 0.10 per share. All securities issued in connection with the financing are subject to a statutory hold period expiring four months and one day from the securities' issuance date. Board Change • Oct 31
High number of new directors Member of Advisory Board Navdeep Nanda was the last director to join the board, commencing their role in 2020. Board Change • Sep 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. COO & Director Rahul Kushwah is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Annuncio • Aug 23
Predictmedix Inc. announced a financing transaction Predictmedix Inc. announced a non-brokered private placement on August 22, 2022.
On the same date, the company has issued 8,300,000 units at a price of CAD 0.05 per unit to investors for gross proceeds of CAD 415,000 in its first tranche. Each unit consists of one common share of the company and one-half of one common share purchase warrant, whereby each warrant entitles the holder to purchase one additional common share for a period of two years from closing at an exercise price of CAD 0.10 per share. All securities issued in connection with the first tranche are subject to a statutory hold period expiring four months and one day from the date of issuance of the securities. Annuncio • Jun 02
Predictmedix Inc. announced delayed 20-F filing On 06/01/2022, Predictmedix Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC. Board Change • Apr 27
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. COO & Director Rahul Kushwah is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Recent Insider Transactions Derivative • Apr 08
President exercised options to buy CA$739k worth of stock. On the 6th of April, Sheldon Kales exercised options to buy 2m shares at a strike price of around CA$0.15, costing a total of CA$244k. This transaction amounted to 5.6% of their direct individual holding at the time of the trade. Since December 2020, Sheldon has owned 29.04m shares directly. Company insiders have collectively bought CA$402k more than they sold, via options and on-market transactions, in the last 12 months. Annuncio • Mar 07
Predictmedix Inc. announced that it has received CAD 1.090085 million in funding Predictmedix Inc. (CNSX:PMED) announced a non-brokered private placement of 3,114,529 units at a price of CAD 0.35 per unit for gross proceeds of CAD 1,090,085 on March 5, 2021. Each unit consists of one common share and one warrant. Each warrant entitles the holder to acquire one common share of the company at a price of CAD 0.50 per common share for a period of 24 months after the closing. The securities are subject to a statutory four months and one day hold period from the date of issue in accordance with applicable Canadian securities laws. Annuncio • Feb 05
Predictmedix Inc. Announces Safe Entry Stations to be deployed as a crucial, first line of defence at Tampa's VIP Big Game Weekend Parties Wellness for Humanity has partnered with Predictmedix Inc. and Juiceworks Exhibits (JUICEWORKS) to deploy Safe Entry Stations at this weekend's Big Game festivities in Tampa, Florida. E11EVEN Miami has teamed up with Dave Portnoy & Barstool Sports alongside Pied Piper Productions to throw two parties in Tampa, Florida, leading up to Sunday's Big Game. These will be two of five parties taking place at WTR, a beautiful 20,000 square foot outdoor space located on The Godfrey property in Tampa, Florida. Rigorous safety protocols were designed to protect partygoers, staff and all involved throughout the entirety of this much-anticipated weekend. Prior to entering the space, attendees will pass through a Safe Entry Station which will screen them for multiple symptoms associated with COVID-19. Developed by infectious disease clinicians and data scientists, Safe Entry Stations are powered by Artificial Intelligence and operate in an autonomous and time-efficient fashion. These Safe Entry Stations comprise the first step in a safety-first triage process. If the Safe Entry Station does not clear the attendee, they will have an additional level of testing provided by Wellness 4 Humanity through a rapid antigen test that provides results in 15 minutes. Is New 90 Day High Low • Jan 21
New 90-day low: CA$0.28 The company is down 47% from its price of CA$0.53 on 22 October 2020. The Canadian market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 26% over the same period. Is New 90 Day High Low • Jan 05
New 90-day low: CA$0.32 The company is down 46% from its price of CA$0.58 on 06 October 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 10.0% over the same period. Annuncio • Dec 03
Wellness 4 Humanity Partners Set to Deploy and Offer Safe Entry Stations At Simon Mall’s Houston Galleria Wellness 4 Humanity was one of the first on the scene to offer disruptive Covid-19 testing to support communities and organizations throughout the pandemic. The Wellness 4 Humanity team has a passion for making the world a better place through social impact, business, company culture, and personal development using cutting edge science. It's these same values that make them an ideal partner to deploy Safe Entry Stations, powered by PredictMedix and Juiceworks Exhibits. Designed by infectious disease experts, along with a AI team, the Safe Entry Stations use artificial intelligence to analyze seven different symptoms associated with COVID-19 with the virus, providing results in seconds. As trusted safety partners to Wellness 4 Humanity, JUICEWORKS and PredictMedix will work together to deploy units to their Fortune 500 group of clients globally. Annuncio • Nov 27
Predictmedix Inc., Annual General Meeting, Jan 28, 2021 Predictmedix Inc., Annual General Meeting, Jan 28, 2021. Annuncio • Nov 20
Predictmedix and Paras Defence & Space Technologies to Launch Predictmedix’s Proprietary Technologies in the Government and Public Sectors Predictmedix Inc. announced that the company is partnering with Paras Defence & Space Technologies Ltd. Together, Paras and Predictmedix have identified significant business opportunities in the government and the public sector in India. Predictmedix will be working with Paras to launch its infectious disease symptom screening technology along with impairment screening technology within these sectors. Is New 90 Day High Low • Nov 11
New 90-day low: CA$0.43 The company is down 47% from its price of CA$0.81 on 12 August 2020. The Canadian market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is down 17% over the same period. Is New 90 Day High Low • Oct 27
New 90-day low: CA$0.48 The company is down 49% from its price of CA$0.95 on 28 July 2020. The Canadian market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is down 3.0% over the same period. 